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VIM-2–producing
Pseudomonas 
putida, Buenos
Aires 
To the Editor: Pseudomonas
putida infections (0.03% of isolates
from the culture collection of inpa-
tients, SIR Program 2003–2004,
www.aam.org.ar) are mainly reported
in immunocompromised patients,
such as newborns, neutropenic
patients, and cancer patients. They are
usually susceptible to extended-spec-
trum cephalosporins, aminoglyco-
sides, fluoroquinolones, and car-
bapenems. However, isolates have
been identified that produce acquired
metallo-β-lactamases (MBLs) and are
resistant to most β-lactams, including
carbapenems.
Two multidrug-resistant P. puti-
da isolates were obtained from clini-
cal samples at the Sanatorio Mater
Dei in Buenos Aires. One isolate was
obtained in March 2005 from a urine
specimen of a 76-year-old woman
with a urinary tract infection who was
using a urethral catheter. The second
isolate was obtained in May 2005
from a tracheal aspirate of a 67-year-
old man with nosocomial pneumonia.
Bacteria were identified by using
conventional biochemical tests and
the API 20NE System (API,
bioMérieux, Lyon, France). Sus-
ceptibility tests were performed
according to standard procedures.
Both isolates were resistant to imi-
penem and meropenem (MICs >32
µg/mL) but were susceptible to
amikacin and colistin. Susceptibility
data are shown in the Table.
Screening for MBLs was per-
formed by using a double-disk diffu-
sion method. Disks containing 1 µmol
EDTA (metal chelator) were placed
on Mueller-Hinton agar plates con-
taining the 2 isolates. Disks contain-
ing carbapenem were placed 15 mm
from disks containing EDTA. An
increase in the inhibition zone of the
disk containing drug near the disk
containing EDTA was observed for
both isolates, which suggested the
presence of MBLs. 
PCR amplification of imp and vim
genes was conducted by using primers
based on conserved regions of the imp
and vim genes (blaIMP-F: 5′-GAAG-
GCGTTTATGTTCATACTT-3′,
blaIMP-R: 5′-GTTTGCCTTACCAT
ATTTGGA-3′, blaVIMG-F: 5′-GGT-
GTTTGGTCGCATATC-3′, and bla
VIMG-R 5′-TGGGCCATTCAGC
CAGATC-3′) and heat-extracted DNA
as template. Reactions were per-
formed in a T-gradient instrument
(Biometra, Göttingen, Germany) with
the following reaction conditions: 1
cycle at 95°C for 5 min, 52°C for 15
min, and 72°C for 6 min, followed by
30 cycles at 95°C for 1 min, 52°C for
1 min, and 72°C for 1 min, and a final
reaction at 72°C for 20 min. Amplified
fragments were sequenced on both
strands by using an ABI Prism DNA
3700 (Applied Biosystems, Foster
City, CA, USA), and nucleotide
sequences were compared by using
BLAST (National Center for
Biotechnology Information, Bethesda,
MD, USA, www.ncbi.nlm.nih.gov/
Tools/). Nucleotide sequences were
completely homologous to the vim-2
coding gene.
Two repetitive-element–based
PCR (rep-PCR) assays (ERIC-PCR
and REP-PCR) with primers REP-1
(5′-IGCGCCGICATCAGGC-3′),
REP-2 (5′-CGTCTTATCAGGCC-
TAC-3′), ERIC-1 (5′-CACTTAGGG
GTCCTCAATGTA-3′), and ERIC-2
(5′-AAGTAAGTGACTGGGGT-
GAGCG-3′) were used to characterize
isolates. PCR conditions were 94°C
for 2 min, 30 cycles at 94°C for 30 s,
50°C for 1 min, and 72°C for 4 min,
and a final reaction at 72°C for 7 min.
Banding patterns were visually ana-
lyzed after electrophoresis of samples.
Variations in band intensity were not
considered to indicate genetic differ-
ences. Banding patterns obtained by
REP-PCR and ERIC-PCR assays
were identical in both isolates (data
not shown).
Among the MBLs acquired by P.
putida, IMP-1 was reported by Senda
et al. in Japan in 1996 (1) and later
reported in Taiwan and Japan (2).
IMP-12 was the first IMP MBL
described in P. putida in Europe (3).
VIM-1 in P. putida was first reported
in Europe (4), and VIM-2 in P. putida
was first reported in Taiwan, Republic
of Korea, Japan, and France (5,6). Our
isolates were resistant to aztreonam
(MIC 64 µg/mL). However, carbapen-
em-susceptible  P.  putida had low
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levels of susceptibility because the
MIC50 was only 1 dilution below the
current breakpoint (7,8). Aztreonam
resistance could not be transferred by
conjugation between IMP-1–produc-
ing (aztreonam-resistant) P.  putida
and P. aeruginosa (2) and is not asso-
ciated with a transposon carrying
blaVIM-2 (6). No evidence of extend-
ed-spectrum β-lactamases was detect-
ed in our isolates by classic synergy
assays with clavulanate plus aztreon-
am, ceftazidime, or cefotaxime. VIM-
6–producing  P.  putida isolates from
Singapore (9) were more resistant to
aztreonam (MIC >128 µg/mL), cef-
tazidime, and cefepime (MIC >256
µg/mL).
Detection of blaVIM-2 in
Pseudomonas in South America was
initially reported by the SENTRY
Antimicrobial Surveillance Program
(10) and included 1 P. fluorescens iso-
late in Chile and 3 P. aeruginosa iso-
lates in Venezuela. To the best of our
knowledge, our report is the first of
VIM-2 in P. putida in Latin America.
VIM-2–producing  P.  putida, which
were originally restricted to East Asia
and only very recently found in
France, may represent an emerging
pathogen or function as reservoirs for
resistance because of their widespread
presence in the hospital environment.
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Multidrug-resistant
Acinetobacter 
baumannii, Russia
To the Editor: During the past
decade, nosocomial infections due to
multidrug-resistant  Acinetobacter
baumannii have been described with
increasing frequency, mostly in inten-
sive care units (ICUs), resulting in
therapeutic difficulties (1). The main
mechanism for resistance to extend-
ed-spectrum cephalosporins in A.
baumannii is attributed to the overex-
pression of chromosome-encoded
cephalosporinases or to plasmid-
encoded Ambler class A, B, and D β-
lactamases (2). A. baumannii that pro-
duce PER-1 extended-spectrum β-lac-
tamase (ESBL) are rarely isolated
outside Turkey and remain suscepti-
ble to carbapenems (3). Here we
describe what we believe is the first
ESBL-producing  A. baumannii iso-
late resistant to carbapenems and the
first characterization of a PER-1 A.
baumannii isolate from Russia, fur-
ther supporting the emergence and
dissemination of PER-1 A. baumannii
strains in eastern Europe and outside
Turkey (3,4).
On April 17, 2005, a 79-year-old-
man was hospitalized in the cardiolo-
gy ward of a private hospital in
Moscow, Russia, with cardiac
arrhythmia and a pulmonary infarc-
tion subsequent to a pulmonary
embolism. After 1 week, he was trans-
ferred to the ICU for multiple organ
failure related to a nosocomial infec-
tion caused by an A. baumannii strain